**FOI Ref: 6399**

**Category(ies): Clinical - Drugs**

**Subject: Intra-vitreal treatments in Ophthalmology**

**Date Received: 19/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am researching the usage of high-cost intra-vitreal treatments in Ophthalmology. Your answers to the following questions will be highly appreciated | |
| 1. How many patients over the last 4 months (January to April 2022) have received the following anti-VEGF treatments for any eye condition:   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Ranibizumab | * Aflibercept – 792 * Bevacizumab – 0 * Brolucizumab – 0 * Dexamethasone – 3 * Ranibizumab – 1040 |
| 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.   * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Ranibizumab | * Aflibercept – 46 * Bevacizumab – 0 * Brolucizumab – 0 * Dexamethasone – 0 * Ranibizumab – 60 |
| 3. Please provide the number of patients treated for Diabetic Macular Oedema (DMO) ONLY in the last 4 months (January to April 2022) with the following:   * Aflibercept * Bevacizumab * Dexamethasone * Ranibizumab | |  |  | | --- | --- | |  | **Eye Conditions** | | **Treatment** | Diabetic Macular Degeneration DMO | | Aflibercept | 201 | | Bevacizumab | 0 | | Dexamethasone | 0 | | Ranibizumab | 232 | |
| 4. Please provide the number of patients treated for Retinal Vein Occlusion (RVO) ONLY in the last 4 months (January to April 2022) with the following:   * Aflibercept * Bevacizumab * Dexamethasone * Ranibizumab | |  |  | | --- | --- | |  | **Eye Conditions** | | **Treatment** | Retinal Vein Occulusion RVO | | Aflibercept | 179 | | Bevacizumab | 0 | | Dexamethasone | 3 | | Ranibizumab | 229 | |